Glutamate release inhibitor / sodium channel blocker

Plain-language summaryIntrigue 72 / 100

Riluzole was the first FDA-approved drug for ALS, cleared in 1995 and the only option until edaravone in 2017. It hits glutamate signaling from several angles at once: it blocks sodium channels (cutting glutamate release from nerve terminals), antagonizes AMPA and kainate receptors on the receiving end, and modestly potentiates GABA. Together these knock down the excitotoxic overdrive that researchers think kills motor neurons in ALS. The clinical effect is honest but small, extending median survival by roughly two to three months. That said, the benefit shows up consistently across trials, which matters. Off-label work has tested it in depression (inspired by ketamine’s glutamate-targeting success), generalized anxiety, and OCD. Reference glutamate-release inhibitor in neuropharmacology. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

49/100

First ALS approval and canonical glutamate release inhibitor with modest effect size and aging novelty profile

Look, riluzole is the compound that kept ALS patients alive a few months longer for nearly two decades, and thats no small thing historically. FDA-approved in 1995, first of its class for ALS, and the drug that forced a real conversation about excitotoxicity as a therapeutic target. We have real respect for what it accomplished. But respect and research novelty are different currencies, and the gap between them is where this score lives.

The mechanism is genuinely multi-target in a way that still holds interest: state-dependent sodium channel blockade reduces glutamate release from presynaptic terminals, combined with postsynaptic AMPA and kainate receptor antagonism and modest GABA-A potentiation. That’s a layered glutamate-reduction profile rather than a clean single-receptor hit. What we like about it mechanistically is precisely that layering, and the fact that it remains the canonical tool for presynaptic glutamate release inhibition in excitotoxicity research. You can’t replicate that role easily with other compounds, and that’s what keeps the bench value score honest.

Where riluzole gets harder to justify as a frontier pick is novelty. Thirty years of literature means the research community has turned it over many times. The ALS efficacy signal is real but modest, median survival extension measured in weeks to a couple of months across replicated trials. The excitotoxicity hypothesis it targets hasn’t produced dramatic new mechanistic territory since. Edaravone arrived in 2017, tofersen more recently. The differentiation case has softened considerably.

The more interesting current angle is off-label psychiatric use, particularly OCD, generalized anxiety, and major depressive disorder. Pittenger’s group at Yale and others have run small-N trials in treatment-resistant OCD with meaningful response rates, and the glutamate hypothesis of MDD has gotten serious institutional attention since ketamine. Riluzole’s slower, gentler glutamate modulation is mechanistically plausible as a maintenance strategy. But the evidence is phase 2 at best, effect sizes are modest, and it’s competing for attention with compounds that are more potent and more exciting to funders.

What this compound does reliably is serve as a reference standard. Any lab working on excitotoxicity, ALS pathomechanisms, or glutamate-dependent neurodegeneration reaches for riluzole as a comparator. That keeps it in the library. But investigators looking for frontier signal should look elsewhere. The psychiatric angle is worth watching, not betting your next grant on yet.

Novelty: 28
Mechanism promise: 45
In-category differentiation: 40
Evidence quality: 70
Translational signal: 60
Research bench value: 65

Rationale Riluzole scores well on evidence and translational signal (FDA-approved 1995, replicated trials, confirmed human effect in ALS) but novelty is low for a thirty-year-old compound and differentiation has eroded as newer glutamate modulators emerged. Bench value keeps the overall from falling further because it remains the reference probe for presynaptic glutamate release inhibition in excitotoxicity models.

Glutamate release inhibitor / sodium channel blocker

A benzothiazole glutamate release inhibitor with sodium channel block; the first FDA-approved drug for amyotrophic lateral sclerosis.

Abstract

Riluzole (6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; CAS 1744-22-5; molecular formula C8H5F3N2OS; molecular weight 234.20) is a benzothiazole compound developed at Rhone-Poulenc and approved by the FDA in 1995 (Rilutek) for amyotrophic lateral sclerosis. The compound was the first ALS-approved drug and remained the only one until edaravone in 2017. Mechanism is multifactorial: state-dependent voltage-gated sodium channel inhibition (reducing glutamate release from presynaptic terminals), AMPA and kainate receptor antagonism (postsynaptic glutamate effect), and modest GABA-A potentiation. The combined glutamate-reducing activity addresses the excitotoxicity hypothesis of ALS pathogenesis. Plasma half-life is approximately 12 hours; metabolism is via CYP1A2. The clinical effect in ALS is modest (median survival extension approximately 2 to 3 months) but consistent across trials. Off-label use in major depressive disorder (where ketamine’s NMDA mechanism inspired interest in glutamate modulators), generalized anxiety disorder, and OCD has been investigated. Used as the canonical glutamate release inhibitor in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-376Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Glutamate release inhibitor / sodium channel blocker

Riluzole

Abstract

Read the full monograph